Nikolai Loft

Gentofte Hospital — Denmark

Immunology and Microbiology · Life Sciences

20h-index1.6kcitations82works3.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Psoriasis: Treatment and Pathogenesis(51), Dermatology and Skin Diseases(32), Health Systems, Economic Evaluations, Quality of Life(12), Rheumatoid Arthritis Research and Therapies(9), Pharmaceutical studies and practices(9)

Publications79 total

Drug Survival of Biologics in Bionaive and Bioexperienced Patients With Psoriasis
JAMA Dermatology·2026Open Access
Real-World Evidence of Effectiveness and Safety of Abrocitinib, Baricitinib and Upadacitinib in Atopic Dermatitis: A Systematic Review and Meta-Analysis
American Journal of Clinical Dermatology·2025
Shift from ustekinumab originator to biosimilars in Denmark
Journal of the European Academy of Dermatology and Venereology·2025
Effectiveness and Safety of Delgocitinib Cream in Pustulosis Palmoplantaris: A Case Series
Acta Dermato Venereologica·2025Open Access
Pustular psoriasis following treatment with biologics among patients with plaque psoriasis: a nationwide cohort study
British Journal of Dermatology·2025
Axillary microwave thermolysis in patients with severe primary hyperhidrosis: retrospective case series
Clinical Autonomic Research·2025
Risk of Dyslipidemia Associated With Oral Janus Kinase Inhibitors: A Systematic Review and Meta‐Analysis of Randomized Placebo‐Controlled Trials
International Journal of Dermatology·2025· 1 citedOpen Access
Comparative Cancer Risk in Patients With Psoriasis Treated With Adalimumab, Secukinumab, or Ustekinumab
JAMA Dermatology·2025Open Access
The Association Between Genetics and Response to Treatment with Biologics in Patients with Psoriasis
International Journal of Molecular Sciences·2025Open Access
Adverse Events and Immune Response in Psoriasis Patients Receiving Interleukin-17 Inhibitors
Acta Dermato Venereologica·2025· 2 citedOpen Access
No Change in HbA1c Levels during Treatment with Biologics or Methotrexate in Patients with Psoriasis
Dermatology·2025Open Access
Risk of new or recurrent cancer during treatment with biologics in patients with immune-mediated inflammatory diseases and previous cancer: a meta-analysis
Clinical and Experimental Medicine·2025· 1 citedOpen Access
Real‐world experience of multiple switches between adalimumab biosimilars in patients with psoriasis
Journal of the European Academy of Dermatology and Venereology·2025
Correction to: Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis
American Journal of Clinical Dermatology·2025· 1 citedOpen Access
Multiple Biologics Treatment Failures in Patients with Psoriasis: A Case Series of 4 Patients
Acta Dermato Venereologica·2025Open Access
Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis
American Journal of Clinical Dermatology·2025· 11 cited
Real-world Drug Survival of Biosimilar SB5 vs GP2017 Following a Mandatory Non-medical Switch from Adalimumab Originator for Psoriasis: A Nationwide Cohort Study
Acta Dermato Venereologica·2025Open Access
Worldwide prevalence of prurigo nodularis: A systematic review and meta‐analysis
Journal of the European Academy of Dermatology and Venereology·2025· 2 citedOpen Access
Sex Differences in Dermatology Life Quality Index (DLQI) among Patients with Psoriasis
Acta Dermato Venereologica·2024· 2 citedOpen Access
P70 The 1-year all-cause drug survival of bimekizumab compared with other biologics in psoriasis: a nationwide real-world cohort study
British Journal of Dermatology·2024Open Access
page 1 of 4Next →

Frequent Co-authors

Lone Skov(42), Alexander Egeberg(25), Claus Zachariae(12), Jacob P. Thyssen(11), Mads Kirchheiner Rasmussen(11), Anne‐Sofie Halling(10), Lars Iversen(9), Lars Erik Bryld(7), Kawa Khaled Ajgeiy(6), C. Schwarz(6), C. Nissen(5), Mie Siewertsen(5), Claus Henrik Nielsen(5), Simon Francis Thomsen(4), Vibeke Andersen(4), Tomas Norman Dam(4), Jonathan I. Silverberg(3), Emma Guttman‐Yassky(3), Sofie Vaengebjerg(3), David Thein(3)